Atreya R, Ferrante M, Panaccione R, Feagan B, et al. Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies. J Crohns Colitis 2024 Nov 1:jjae164. doi: 10.1093.
PMID: 39485390